within Pharmacolibrary.Drugs.ATC.V;

model V03AX04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.056666666666666664,
    adminDuration  = 600,
    adminMass      = 0.0005,
    adminCount     = 1,
    Vd             = 0.0115,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Difelikefalin is a selective kappa opioid receptor agonist, used for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. It is approved for medical use and acts peripherally with minimal crossing of the blood-brain barrier, reducing the risk of central opioid side effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients undergoing hemodialysis, following intravenous administration.</p><h4>References</h4><ol><li><p>Stark, JG, et al., &amp; Menzaghi, F (2023). Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis. <i>Clinical pharmacokinetics</i> 62(9) 1231–1241. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01262-2&quot;>10.1007/s40262-023-01262-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37369955/&quot;>https://pubmed.ncbi.nlm.nih.gov/37369955</a></p></li><li><p>Spencer, RH, et al., &amp; Menzaghi, F (2024). Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus. <i>BMC nephrology</i> 25(1) 351–None. DOI:<a href=&quot;https://doi.org/10.1186/s12882-024-03790-w&quot;>10.1186/s12882-024-03790-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39402448/&quot;>https://pubmed.ncbi.nlm.nih.gov/39402448</a></p></li><li><p>Narita, I, et al., &amp; Gejyo, F (2022). Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial. <i>JAMA network open</i> 5(5) e2210339–None. DOI:<a href=&quot;https://doi.org/10.1001/jamanetworkopen.2022.10339&quot;>10.1001/jamanetworkopen.2022.10339</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35511180/&quot;>https://pubmed.ncbi.nlm.nih.gov/35511180</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V03AX04;
